Evans RN, Reeves BC, Maguire MG, et al. - In this investigation involving 1,731 participants, mean (SD) age 78.6 (7.4) years, from 2 randomized clinical trials, researchers ascertained if visual and anatomic outcomes in eyes with neovascular age-related macular degeneration (nAMD) starting anti-vascular endothelial growth factor (VEGF) treatment are correlated with fluctuations in retinal thickness. In these post hoc analyses, greater variation in retinal thickness in eyes with nAMD during treatment with anti-VEGF was correlated with worse best-corrected visual acuity and development of fibrosis and macular atrophy, despite protocol-directed treatment frequency. When advising patients about their prognosis, practitioners may want to consider differences in retinal thickness.